Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueEBIATGross ProfitLeasesLong-Term Debt IssuancesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetReceivables - OtherShares OutstandingShares OutstandingShort-Term Debt issuancesShort-Term Debt repayments
Ratios

China Pharma Holdings (CPHI) Other Gross PP&E Adjustments (2016 - 2025)

China Pharma Holdings filings provide 15 years of Other Gross PP&E Adjustments readings, the most recent being $37.6 million for Q4 2025.

  • On a quarterly basis, Other Gross PP&E Adjustments rose 2.0% to $37.6 million in Q4 2025 year-over-year; TTM through Dec 2025 was $37.6 million, a 2.0% increase, with the full-year FY2025 number at $37.6 million, up 2.0% from a year prior.
  • Other Gross PP&E Adjustments hit $37.6 million in Q4 2025 for China Pharma Holdings, up from $37.3 million in the prior quarter.
  • In the past five years, Other Gross PP&E Adjustments ranged from a high of $37.9 million in Q3 2024 to a low of -$25369.0 in Q1 2021.
  • Median Other Gross PP&E Adjustments over the past 5 years was $32.7 million (2022), compared with a mean of $20.3 million.
  • Biggest five-year swings in Other Gross PP&E Adjustments: plummeted 105.37% in 2021 and later soared 6978.34% in 2024.
  • China Pharma Holdings' Other Gross PP&E Adjustments stood at $488309.0 in 2021, then soared by 5733.46% to $28.5 million in 2022, then surged by 31.21% to $37.4 million in 2023, then dropped by 1.31% to $36.9 million in 2024, then rose by 2.0% to $37.6 million in 2025.
  • The last three reported values for Other Gross PP&E Adjustments were $37.6 million (Q4 2025), $37.3 million (Q3 2025), and $37.2 million (Q2 2025) per Business Quant data.